Apricus Biosciences Inc Share Price Nasdaq
Equities
US03832V1098
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
16/05 | Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding | CI |
14/05 | Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance | MT |
Sales 2022 | - | Sales 2023 | 2.2 183.84 | Capitalization | 13.61M 1.14B |
---|---|---|---|---|---|
Net income 2022 | -73M -6.09B | Net income 2023 | -37M -3.09B | EV / Sales 2022 | - |
Net Debt 2022 | 4.59M 383M | Net Debt 2023 | 11.23M 937M | EV / Sales 2023 | 1,12,78,476 x |
P/E ratio 2022 |
-0.98
x | P/E ratio 2023 |
-0.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.99% |
Latest transcript on Apricus Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 64 | 01/87/01 |
Director of Finance/CFO | 52 | 01/19/01 | |
Karen Fusaro
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 77 | 01/21/01 | |
Richard Pascoe
CHM | Chairman | 60 | 01/13/01 |
Daniel O'Connor
BRD | Director/Board Member | 59 | 01/19/01 |
1st Jan change | Capi. | |
---|---|---|
+16.42% | 122B | |
+19.68% | 115B | |
+21.22% | 26.64B | |
-23.67% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-18.37% | 15.49B | |
+62.49% | 14.83B | |
+2.06% | 13.67B |